FDA’s Echometrix EchoSoft™ Clearance Takes Ultrasound Diagnostics Up A Notch

“The FDA’s clearance of EchoSoft will help patients and clinicians better understand musculoskeletal conditions at both initial diagnosis and during rehabilitation. By enabling wider use of ultrasound for musculoskeletal evaluation with our EchoSoft product, we can lower medical imaging costs by helping to reduce dependence on MRI.”

In short

U.S company Echometrix LLC has announced that it has received U.S. FDA clearance to market its EchoSoft™ ultrasound technology, which the company claims provides a new level of information from diagnostic ultrasound tests.

Background

EchoSoft is Echometrix’ first commercial offering. It is a powerful software package that is used with diagnostic ultrasound to assist with the diagnosis and monitoring of musculoskeletal conditions. EchoSoft’s proprietary technology generates color maps to help trained clinicians visualise structural characteristics that are unique to tendons and ligaments. This information is not available through the use of diagnostic ultrasound equipment or conventional software packages.

Although the company’s core technology can be used for a range of applications, Echometrix has focused on the musculoskeletal system because the emerging market is growing rapidly. The U.S. musculoskeletal ultrasound market is projected to grow by 27 percent per year, reaching $93 million annually by 2015, according to Frost and Sullivan.

EchoSoft is designed for compatibility with ultrasound equipment produced by all major manufacturers. The company estimates that there are roughly 24,000 ultrasound machines in use for musculoskeletal evaluation in U.S. healthcare institutions today.

Echometrix continues to participate in a range of longitudinal clinical studies with partners in the United States, Canada and Australia.

Company comments

“We are very pleased to have reached this critical milestone in our company’s history,” said Sam Adams, the company’s CEO. “The FDA’s clearance of EchoSoft will help patients and clinicians better understand musculoskeletal conditions at both initial diagnosis and during rehabilitation. By enabling wider use of ultrasound for musculoskeletal evaluation with our EchoSoft product, we can lower medical imaging costs by helping to reduce dependence on MRI.

“By achieving this milestone, we have created significant value, not only for clinicians and patients, but for our shareholders, as well,” Mr. Adams said.

Source: Echometrix LLC., Business Wire